Semaxanib

Semaxanib

Clinical data
ATC code	none
Identifiers
IUPAC name (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
CAS Number	194413-58-6 N
PubChem CID	5329098
IUPHAR/BPS	5056
ChemSpider	4486260 Y
UNII	71IA9S35AJ
ChEBI	CHEBI:91083 N
ChEMBL	CHEMBL276711 Y
Chemical and physical data
Formula	C15H14N2O
Molar mass	238.285 g/mol
3D model (JSmol)	Interactive image
SMILES O=C2C(\c1ccccc1N2)=C/c3c(cc(n3)C)C
InChI InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8- Y Key:WUWDLXZGHZSWQZ-WQLSENKSSA-N Y
NY (what is this?)

Semaxanib (SU5416) is a tyrosine-kinase inhibitor drug designed by SUGEN as a cancer therapeutic. It is an experimental stage drug, not licensed for use on human patients outside of clinical trials. Semaxanib is a potent and selective synthetic inhibitor of the Flk-1/KDR vascular endothelial growth factor (VEGF) receptor tyrosine kinase. It targets the VEGF pathway, and both in vivo and in vitro studies have demonstrated antiangiogenic potential.

On February 2002, Pharmacia, the then-parent of Sugen, prematurely ended Phase III clinical trials of semaxinib in the treatment of advanced colorectal cancer due to discouraging results. Other studies, at earlier phases, have since been conducted. However, due to the prospect of next-generation tyrosine kinase inhibitors and the inefficacy of semaxanib in clinic trials, further development of the drug has been discontinued. A related compound, SU11248 was further developed by Sugen, and then by Pfizer and was FDA-approved as sunitinib (Sutent) for treatment of renal carcinoma in January 2006.